Stay updated on BBI608 Pembrolizumab Combination: Clinical Trial
Sign up to get notified when there's something new on the BBI608 Pembrolizumab Combination: Clinical Trial page.

Latest updates to the BBI608 Pembrolizumab Combination: Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.5.0 to v3.5.2. No changes to study details or visible content.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check37 days agoChange DetectedRevision: v3.4.3 updated from v3.4.2. The change is a site-wide version label visible on the page footer.SummaryDifference0.1%

- Check66 days agoChange DetectedA new page revision tag v3.4.2 is added and a previous funding notice about government operating status is removed. No study content, results, eligibility criteria, enrollment numbers, or navigation elements are altered.SummaryDifference0.5%

- Check73 days agoChange DetectedA site-wide notice about a lapse in government funding and a version update to v3.4.1 were added; the previous version was v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check80 days agoChange DetectedShow glossary was added; metadata labels were updated (Last Update Submitted that Met QC Criteria and No FEAR Act Data) with Revision: v3.4.0 to replace v3.3.4. These changes are editorial and UI-focused and do not modify study data, eligibility criteria, or core functionality.SummaryDifference0.2%

Stay in the know with updates to BBI608 Pembrolizumab Combination: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBI608 Pembrolizumab Combination: Clinical Trial page.